{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-25-000090","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.098415+00:00","generated_at":"2026-05-16T22:40:43.769633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs","bullets":["Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).","R&D spend $141.2M, down 10% YoY; plans ~60% reduction in direct R&D spend going forward.","Cash and equivalents $263.8M as of Sep 30, 2025.","Restructuring: focus on opakalim (Kv7), extracellular degraders (BHV-1400/1300), and taldefgrobep (myostatin); other programs paused/halted.","FDA Type A meeting requested to appeal CRL for SCA drug VYGLXIA; Phase 2 opakalim depression data expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-25-000090","json":"https://secwatch.observer/filing/0001935979-25-000090.json","markdown":"https://secwatch.observer/filing/0001935979-25-000090.md","text":"https://secwatch.observer/filing/0001935979-25-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/0001935979-25-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597925000090/bhvn-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:40:43.769633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}